Director at IGC Pharma (IGC) receives 170,000 shares from RSUs
Rhea-AI Filing Summary
IGC Pharma director Richard K. Prins exercised restricted stock units into common shares of the company. On April 1, 2026, he converted 170,000 restricted stock units into 170,000 shares of common stock at an exercise price of $0.00 per share. Following these transactions, he directly holds 1,541,251 shares of IGC Pharma common stock. The units were granted in June 2023 and March 2024 and vest in equal installments over three years, with each unit representing one share of common stock.
Positive
- None.
Negative
- None.
Insights
Director converts 170,000 RSUs into shares as part of routine vesting.
Director Richard K. Prins exercised restricted stock units granted in June 2023 and March 2024, receiving 170,000 shares of IGC Pharma common stock at $0.00 per share. These RSUs vest in equal installments over three years.
After the transactions, Prins directly holds 1,541,251 shares, and no remaining derivative positions are shown. Because there were no open‑market purchases or sales and the events stem from compensation vesting, this looks like a routine equity award exercise rather than a directional bet on the stock.
Insider Trade Summary
170,000 shares exercised/converted
Mixed
4 txns
Insider
PRINS RICHARD K
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 100,000 | $0.00 | -- |
| Exercise | Restricted Stock Units | 70,000 | $0.00 | -- |
| Exercise | Common Stock | 100,000 | $0.00 | -- |
| Exercise | Common Stock | 70,000 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Common Stock — 1,471,251 shares (Direct)
Footnotes (1)
- On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2024. On March 13, 2024, the Reporting Person was granted RSUs subject to vesting equally over three years starting March 2025. Each restricted stock unit represents a right to receive one share of IGC common stock.
Key Figures
RSUs exercised: 170,000 units
Shares from RSUs: 170,000 shares
Post-transaction holdings: 1,541,251 shares
+3 more
6 metrics
RSUs exercised
170,000 units
Restricted stock units converted to common shares on April 1, 2026
Shares from RSUs
170,000 shares
Common stock received upon RSU exercise at $0.00 per share
Post-transaction holdings
1,541,251 shares
Director’s direct IGC Pharma common stock position after exercises
First RSU grant date
June 20, 2023
RSUs vest equally over three years starting March 31, 2024
Second RSU grant date
March 13, 2024
RSUs vest equally over three years starting March 2025
Exercise price
$0.00 per share
Price per share for common stock received from RSU conversion
Key Terms
Restricted Stock Units, RSUs, Exercise or conversion of derivative security, derivative security, +2 more
6 terms
Restricted Stock Units financial
"On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"On March 13, 2024, the Reporting Person was granted RSUs subject to vesting equally over three years"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
derivative security financial
"transaction_type": "derivative", "transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting equally over three years financial
"was granted RSUs subject to vesting equally over three years starting on March 31, 2024"
restricted stock unit financial
"Each restricted stock unit represents a right to receive one share of IGC common stock."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did IGC (IGC) director Richard K. Prins report in this Form 4?
Director Richard K. Prins reported exercising restricted stock units into common shares. He converted 170,000 RSUs into 170,000 IGC Pharma common shares at $0.00 per share, reflecting vesting of prior equity grants rather than an open-market stock purchase or sale.
Were the IGC Pharma RSU exercises open-market purchases or sales?
The RSU exercises were not open-market purchases or sales. They represent the conversion of previously granted restricted stock units into common shares at a stated price of $0.00 per share, consistent with standard equity compensation vesting rather than discretionary trading in the market.
When were the IGC Pharma RSUs granted and how do they vest?
One RSU grant was made on June 20, 2023 and another on March 13, 2024. The awards vest in equal installments over three years, starting March 31, 2024 for the 2023 grant and March 2025 for the 2024 grant, with each vested unit delivering one common share.
Does Richard K. Prins have remaining derivative positions after these IGC RSU exercises?
No remaining derivative positions appear in this Form 4 after the exercises. The derivative section shows RSUs exercised into common stock, and the derivative position summary is empty, indicating that the reported units were fully converted to shares in these transactions.